Some analysts say generic drugmakers will be ill-suited to produce complex follow-on biologics given the case-by-case standard Congress is considering in legislation to create an abbreviated approval pathway. That could leave the door open for pharma and biotech companies to lead the market, this RPM Report analysis says.

Related Summaries